Lung cancer risk in relation to mephenytoin hydroxylation activity

被引：14

作者：

Benhamou, S

Bouchardy, C

Dayer, P

机构：

[1] GENEVA CANC REGISTRY,CH-1205 GENEVA,SWITZERLAND

[2] UNIV HOSP GENEVA,DIV CLIN PHARMACOL,CH-1211 GENEVA,SWITZERLAND

来源：

PHARMACOGENETICS | 1997年 / 7卷 / 02期

关键词：

lung cancer; CYP2C19 activity smoking; epidemiology;

D O I：

10.1097/00008571-199704000-00011

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

[No abstract available]

引用

收藏

页码：157 / 159

页数：3

相关论文

共 11 条

[1] [Anonymous], 1986, IARC MON EV CARC RIS
[2] AYESH R, 1985, MICROSOMES DRUG OXID, P340
[3] Benhamou S, 1996, CANCER EPIDEM BIOMAR, V5, P683
[4] Bouchardy C, 1996, CANCER RES, V56, P251
[5] Breslow N.E., 1980, STAT METHODS CANC RE, P192
[6] Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole
Caraco, Y
Wilkinson, GR
Wood, AJJ
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (04) : 396 - 404
[7] RAPID SCREENING FOR POLYMORPHISMS IN DEXTROMETHORPHAN AND MEPHENYTOIN METABOLISM
GUTTENDORF, RJ
BRITTO, M
BLOUIN, RA
FOSTER, TS
JOHN, W
PITTMAN, KA
WEDLUND, PJ
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 29 (04) : 373 - 380
[8] PHENOTYPING POLYMORPHIC DRUG-METABOLISM IN THE FRENCH CAUCASIAN POPULATION
JACQZ, E
DULAC, H
MATHIEU, H
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (02) : 167 - 171
[9] KAISARY A, 1987, CANCER RES, V47, P5488
[10] MEPHENYTOIN HYDROXYLATION POLYMORPHISM - CHARACTERIZATION OF THE ENZYMATIC DEFICIENCY IN LIVER-MICROSOMES OF POOR METABOLIZERS PHENOTYPED INVIVO
MEIER, UT
DAYER, P
MALE, PJ
KRONBACH, T
MEYER, UA
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 38 (05) : 488 - 494